The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| EVLO | +66.67% | -100% | -91.16% | -100% |
| S&P | +15.06% | +95.03% | +14.29% | +150% |
Evelo Biosciences, Inc. operates as a clinical stage biotechnology company, which engages in the development of orally delivered investigational medicines. Its portfolio includes EDP1066 and EDP1815 for the treatment of inflammatory diseases, EDP2939 for inflammation, and EDP1908 for oncology. The company was founded by Noubar B. Afeyan and David A. Berry in 2014 and is headquartered in Cambridge, MA.
Currently no data to display
Currently no data to display.
Currently no data to display.
| Metric | YoY Change |
|---|
EVLO earnings call for the period ending June 30, 2022.
EVLO earnings call for the period ending December 31, 2021.
EVLO earnings call for the period ending September 30, 2021.
EVLO earnings call for the period ending June 30, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
